Stock listing

Valbiotis Sa

Selected listing: ALVAL · EURONEXT · EUR · FR

Valbiotis Sa (Euronext:ALVAL), Health Technology. Latest release Sep 22, 2026: VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver…

ALVAL:EURONEXTEURFRUpdated October 3, 2026

Ticker: Euronext:ALVAL
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Euronext
Currency: EUR

About Valbiotis Sa

The company focuses on the development of innovative solutions for the prevention and management of metabolic diseases. Valbiotis is committed to advancing research and delivering products that address significant health challenges.

Latest news from Valbiotis Sa

VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23

September 22, 2026

VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63

July 22, 2026

VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M

June 26, 2026

VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%

June 8, 2026

VALBIOTIS SA: Valbiotis continues its expansion in Asia

May 11, 2026

All Valbiotis Sa news →

Research Valbiotis Sa

Valbiotis Sa company profile

View the public company page for Valbiotis Sa on 6ix.

Valbiotis Sa news

Read company news and market updates connected to Valbiotis Sa.

Valbiotis Sa investor events

Find investor webinars, events, and replay context for Valbiotis Sa.